Prices for generic heart failure drugs vary widely

November 15, 2016

NEW ORLEANS, Nov. 15, 2016 -- Prices for generic drugs to treat heart failure can vary so widely that uninsured patients may not be able to afford them, according to preliminary research presented at the American Heart Association's Scientific Sessions 2016.

Researchers surveyed 175 pharmacies in the greater St. Louis area encompassing eastern Missouri and neighboring Illinois to assess how much they charged uninsured customers for three generic medicines used to treat the heart-pumping problem known as heart failure: digoxin, lisinopril and carvedilol.

Researchers found that the combined cash price for the three drugs for 30 days ranged from: "The idea for the study originated with one of our patients, a 25-year-old man with heart failure, who called the office and said he could not afford to fill a prescription for digoxin," said Paul J. Hauptman, M.D., study senior author and professor of medicine and a cardiologist specializing in the care of patients with heart failure at Saint Louis University School of Medicine in Missouri. "When I found out that a month's supply was going to cost him $100, I couldn't believe it. Like me, I think a lot of doctors assume that if you're writing a prescription for a generic drug that it will be affordable -- and that's not necessarily the case."

The study did not find a link between price and type of pharmacy, or median income associated with the zip code in which the pharmacy is located. Surprisingly, two major pharmacy chains did not have consistent pricing across their own stores.

Hauptman added that it is common for patients with heart failure to take five or six medicines to treat the condition, making it even more difficult for patients to get the lowest combined price of the drugs they need.

"It's not reasonable to expect patients who are sick and of limited financial means to call or visit half a dozen pharmacies to get the best price," he said. "What is more likely to happen is that patients visit a pharmacy and find out that the drug is too expensive, so they don't fill the prescription and therefore do not garner benefit from guideline-directed medical therapy."

Since a greater understanding of pricing practices at the retail pharmacy level is required, the researchers said their study should be replicated across other parts of the country and with different generic drugs to treat other medical conditions.

Hauptman said he would expect the results of such studies to be similar. "With heart failure, we have a chronic condition that affects millions of people and usually requires treatment with several drugs. Why would it be different for other conditions?"

The results of these analyses may have significant policy implications given the potential impact on costs borne by patients and adverse outcomes if generic medications are no longer affordable for vulnerable patients who are uninsured or underinsured.

Heart failure doesn't mean that your heart has stopped beating. It means that your heart isn't pumping blood as it should. The heart keeps working, but the body's need for blood and oxygen isn't being met.

According to the American Heart Association about 5.7 million Americans are living with heart failure today. In fact, it's one of the most common reasons people age 65 and older go into the hospital.
-end-
Co-authors are Zackary D. Goff, B.S.; Andrija Vidic, D.O.; John T Chibnall, Ph.D. and Barry Bleske, Pharm.D. Author disclosures are on the abstract.

Note: Scientific presentation time is 1:30 p.m. CT, Tuesday, Nov. 15 in Science and Technology Hall, Population Science Section.

Additional Resources: Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at http://www.heart.org/corporatefunding.

American Heart Association

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.